Connect with iLet Bionic Pancreas
Dexcom G7 powers the iLet Bionic Pancreas—only requiring the user’s weight to get started. The iLet reduces the need to make decisions about your diabetes management—because it makes the decisions for you.
The iLet Bionic Pancreas automatically adjusts to your insulin needs so you don’t have to.
No carb counting*
Just provide an estimate of the carbs in your meal by selecting from 3 options: usual for me, more, or less.
*User must be carb aware.
No corrections
iLet learns about you—your basal insulin needs, how to correct you to target, and how much insulin you need for your meals.
Image shown does not include required overpatch. Please be sure to follow instructions for using the overpatch.
Simple setup
No settings are required to be entered or adjusted—the iLet only needs your weight to get started.
Image shown does not include required overpatch. Please be sure to follow instructions for using the overpatch.
Go Bionic.
Dexcom G7— the most accurate CGM system1,2 that communicates directly with your iLet.
iLet Bionic Pancreas—reduces the need to make decisions about your diabetes management by making them for you based on your Dexcom CGM readings.
Meet Dexcom G7
With Dexcom CGM, you have the option to choose the insulin pump that works best for you. Glucose readings are sent to your smartphone† or Dexcom receiver—without fingersticks.‡
‡Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Image shown does not include required overpatch. Please be sure to follow instructions for using the overpatch.
†For a list of compatible devices, visit www.dexcom.com/compatibility For full Beta Bionics safety information, please visit www.betabionics.com/safety
1 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K213919. Published December 7, 2022. https://www.accessdata.fda.gov/cdrh_docs/reviews/K213919.pdf. 2 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K222447. Published March 3, 2023. https://www.accessdata.fda.gov/cdrh_docs/reviews/K222447.pdf.
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
For full Beta Bionics safety information, please visit www.betabionics.com/safety
Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. ©2023 Dexcom, Inc. All rights reserved. MAT-0658